Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450139 | 0.79 | — | — | |
| SCHEMBL3939163 | 0.76 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CCYP1A2SMN1; SMN2 | |
| SCHEMBL21101528 | 0.69 | — | — | |
| SCHEMBL28609917 | 0.68 | MAPT (0.47) | CYP1A2SMN1; SMN2 | |
| SCHEMBL15049898 | 0.68 | SLC40A1 (0.48) | SMN1; SMN2 | |
| SCHEMBL31596390 | 0.68 | — | — | |
| SCHEMBL5272146 | 0.68 | CYP1A2 (0.30) | CYP1A2SMN1; SMN2 | |
| SCHEMBL160465 | 0.68 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CCYP1A2SMN1; SMN2 | |
| SCHEMBL19293287 | 0.68 | NPC1 (0.33) | ADRA2AADRA2BADRA2CCYP1A2SMN1; SMN2 | |
| SCHEMBL325377 | 0.68 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057832-A1 | USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2025-02-20 | — | — | US | claimed |
| EP-4454647-A1 | USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | claimed |
| CN-117999076-A | Application of 1, 4-dihydro-naphthyridine derivatives in treatment of tumors | 南京宁丹新药技术有限公司 | 2024-05-07 | — | — | CN | claimed |
| WO-2023116304-A1 | USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS | 南京宁丹新药技术有限公司 | 2023-06-29 | — | — | WO | claimed |
| CN-116327761-A | Application of 1, 4-dihydro-naphthyridine derivatives in treatment of tumors | 南京宁丹新药技术有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-117999076-B | Application of 1, 4-dihydro-naphthyridine derivatives in treatment of tumors | 南京宁丹新药技术股份有限公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-121226365-A | 1, 4-Dihydro-1, 8-naphthyridine derivative compound, and pharmaceutical composition and application thereof | 南京宁丹新药技术股份有限公司 | 2025-12-30 | — | — | CN | disclosed |
| CN-121226365-A | 1, 4-Dihydro-1, 8-naphthyridine derivative compound, and pharmaceutical composition and application thereof | 南京宁丹新药技术股份有限公司 | 2025-12-30 | — | — | CN | disclosed |
| WO-2025256620-A1 | 1,4-DIHYDRO-1,8-NAPHTHYRIDINE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 南京宁丹新药技术股份有限公司 | 2025-12-18 | — | — | WO | disclosed |
| WO-2025256620-A1 | 1,4-DIHYDRO-1,8-NAPHTHYRIDINE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 南京宁丹新药技术股份有限公司 | 2025-12-18 | — | — | WO | disclosed |
| EP-4454647-A4 | USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS | NEURODAWN PHARMACEUTICAL CO LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250057832-A1 | USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2025-02-20 | — | — | US | disclosed |
| US-7183412-B2 | Ester or amide derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183412-B2 | Ester or amide derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183412-B2 | Ester or amide derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050090497-A1 | Novel ester or amide derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-04-28 | — | — | US | disclosed |
| US-6822098-B2 | CARBOCYCLIC CARBO, OXO AMINES SUCH AS N-HEPTYL-3-METHYL-4-OXO -1,4-DIHYDROQUINOLINE-2-CARBOXAMIDE, USED FOR PROPHYLAXIS OF GASTROINTERSTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20040019214-A1 | Novel ester or amide derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1314726-A1 | NOVEL ESTER OR AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019214-A1 | Novel ester or amide derivatives | CYP3A7, UGT2B7, NAT1 | ADRA2A 693/4885ADRA2B 445/4885ADRA2C 318/4885 |
| US-20250057832-A1 | USE OF A CLASS OF 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVES IN TREATMENT OF TUMORS | DPYD, TP53, VHL | ADRA2A 3255/4885ADRA2B 3340/4885ADRA2C 3119/4885 |
| US-20050090497-A1 | Novel ester or amide derivatives | CYP3A7, CYP7A1, UGT2B7 | ADRA2A 758/4885ADRA2B 497/4885ADRA2C 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.